
    
      The study will enroll up to 50 patients (up to 50 eyes) with DMO or RVO across two treatment
      groups (Low Dose and High Dose). Patients will be identified and recruited through the clinic
      population of ophthalmology centers in Australia and New Zealand, specializing in the
      diagnosis and treatment of retinal diseases. All patients will be followed for a planned
      evaluation period of 18 months.
    
  